WARN Act and Layoffs in Pharmaceuticals and Biotech — What Drug and Biotech Workers Should Know

Drug and biotech companies rarely announce layoffs the way a factory closure does. The cuts arrive as pipeline pivots, post-acquisition integrations, and cash-runway restructurings — and when they are big enough, they show up as WARN notices. Five recent pharmaceutical and biotech filings in the Layoff Atlas registry cover 526 workers, from an 88-person research institute in Los Angeles to a 205-person generic-drug operation in New York. These are reported plans, not confirmed job losses — filings can be amended, delayed, or cancelled before the effective date.

The recent filings

The five filings span California, New York, New Jersey, and Maryland:

• Ellison Medical Institute, Los Angeles, California — 88 workers. The cancer research and biotechnology institute filed notice on November 4, 2026, for 88 permanent job cuts effective January 3, 2027, at its Exposition Boulevard campus — exactly 60 days' notice.
• Crinetics Pharmaceuticals, San Diego, California — 78 workers. The endocrine drug developer's cuts take effect January 4, 2027, following Vertex Pharmaceuticals' $10 billion acquisition, which closed September 1, 2026. The registry listing originally carried a mistyped 2026 effective date; trade reports confirm January 4, 2027.
• InvaGen Pharmaceuticals, Long Island, New York — 205 workers. Two sites: 160 workers in Central Islip and 45 in Hauppauge, both noticed August 28, 2026, and effective November 27, 2026 — 91 days' notice, both permanent layoffs.
• Teva Pharmaceuticals USA, Fairfield, New Jersey — 61 workers. Effective February 1, 2027, filed with the New Jersey Department of Labor and Workforce Development. The notice date is unavailable in the record, so the notice period cannot be checked from the filing alone.
• Pharmaceutics International, Hunt Valley, Maryland — 94 workers. Notice published October 30, 2026, effective December 29, 2026 — exactly 60 days. The company is listed as a Jabil Inc. company.

A sixth filing shows the other end of the scale: DesigneRx Pharmaceuticals in Vacaville, California, filed a 7-worker notice effective November 15, 2026 — far below the federal thresholds, a reminder the registry records what employers file, not only qualifying mass layoffs.

Why pharma layoffs look different

Pharmaceutical layoffs follow the drug-development cycle more than the business cycle. Three patterns show up again and again:

Post-acquisition integration. Crinetics is the clearest recent example: Vertex completed a $10 billion acquisition on September 1, 2026, and the 78 San Diego cuts followed as the two companies combined operations. Acquired companies' corporate functions — finance, IT, and administrative roles — are usually the first to go.

Pipeline pivots. When a trial fails or a program is deprioritised, the team behind it is cut. Clinical-stage biotechs run on cash runway, and a restructuring that extends that runway by a few quarters is often the stated reason.

Commercial restructuring. Larger drugmakers cut sales forces when a product line is reorganised. Industry trackers counted 90 biopharma workforce-reduction events in 2026, covering more than 27,446 roles — mostly global announcements, not US WARN filings.

The notice period depends on the state

The federal WARN Act generally requires employers with 100 or more full-time employees to give 60 days' notice of a qualifying mass layoff or plant closing. But the states where pharma concentrates add their own rules, and the recent filings show all three in action:

• California requires 60 days' notice from employers with 75 or more employees — a lower threshold than the federal law. Ellison's 60 days and Crinetics' roughly 62 days both clear it.
• New York requires 90 days' notice from employers with 50 or more employees. InvaGen's 91 days clears that bar by a single day.
• New Jersey requires 90 days' notice, and its law also mandates severance in covered layoffs. Teva's missing notice date means the timing cannot be verified from the public record — a gap worth noting, since the notice date is the fact that makes the 90-day rule checkable.

The state where the site sits, not the company's headquarters, decides which notice rule applies.

What pharma and biotech workers should know

A WARN notice is a notice law, not a payment law. Federal WARN does not require severance; that comes from employer policy, a contract, or a state law like New Jersey's. What the notice does give is time: 60 to 90 days to file for unemployment, check when health coverage ends, and talk to the state's Rapid Response team about retraining.

Three things matter in that window: confirm the filing details, since filings are sometimes amended; keep the notice letter and separation paperwork, because their dates decide benefit deadlines; and check the notice period against the state rule — a short notice period can support a back-pay claim if the employer was covered and no exception applied.

Pharma in the national picture

Nationally, Layoff Atlas currently shows 681 notices and 61,493 reported workers in its 90-day window, with 29 worker counts unavailable. California leads with 22,043 workers, followed by Washington with 17,333 — together 64% of reported workers. Virginia (2,556), Maryland (2,547), and Texas (2,419) follow.

The six weeks ahead total 27,071 workers: November 15 (5,537), November 22 (6,614, the heaviest week), November 29 (6,202), December 6 (857), December 13 (5,310), and December 20 (2,551). The average notice with a reported count covers about 94 workers; InvaGen's 205 is more than double that.

The filings are small next to a 3,445-worker farm closure or a 1,279-worker aviation filing, but for the researchers, technicians, and manufacturing staff named in them, the 60 or 90 days' notice is the whole point of the law: time to prepare.

Data source: Layoff Atlas.